Neurological
Refine Search
Pharmaceutical
Shares of Solasia Pharma shot up 33.3% to 200 yen by close of trading today, after revealing that it has entered into an exclusive license agreement with fellow Japan-based Maruho for commercialization of Solasia’s product SP-04 (PledOx). 11 December 2019
Biotechnology
US pharma major AbbVie and non-profit Scripps Research today announced a collaboration to develop new therapies for a range of diseases, including in the therapeutic areas of oncology, immunology, neurology and fibrosis. 9 December 2019
Biotechnology
US biotech Cassava Sciences, previously known as Pain Therapeutics, was up 41% premarket on Friday on increased volume in reaction to new data from a Phase IIa clinical trial evaluating lead drug, PTI-125, in patients with mild-to-moderate Alzheimer's disease (AD). 9 December 2019
Pharmaceutical
Company and product acquisitions featured in the news last week, first with Japan’s Astellas Pharma announcing a $3 billion bid for US biotech Audentes Therapeutics, marking a major move into gene therapy. Also, Canada’s Xenon Pharmaceuticals on Monday entered a licensing deal with Neurocrine Biosciences for its epilepsy candidate XEN901. An additional Food and Drug Administration indication approval for Roche’s Tecentriq in lung cancer sets up immune-oncology competition with Merck & Co’s Keytruda. On the research front, there was disappointment on Thursday for Sage Therapeutics, whose depression drug SAGE-217 failed in a Phase III trial, and Biogen presented new data on two studies of its previously shelved Alzheimer’s disease candidate aducanumab. 8 December 2019
Pharmaceutical
Connecticut, USA-based neurology specialist Biohaven Pharmaceutical saw its shares rise as much as 11.6% pre-market, after it announced successful completion of a pre-planned interim futility analysis for the T2 Protect AD Study. 6 December 2019
Pharmaceutical
After US biotech Biogen presented further analysis from two Phase III trials of its Alzheimer’s candidate, aducanumab, the company’s stock price closed more than 3% up on Thursday. 6 December 2019
Pharmaceutical
Hopes for Sage Therapeutics’ GABAA receptor modulator SAGE-217 were dealt a blow on Thursday, as the firm announced negative results from a key Phase III trial. 5 December 2019
Pharmaceutical
Keeping up the recent momentum of positive news on its CNS drug pimavanserin, Acadia Pharmaceuticals today presented top-line results from its Phase III HARMONY study at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting, December 4 -7, 2019 in San Diego, California, sending the firm’s share up 10% pre-market. 5 December 2019
Biotechnology
Idoesia has granted Japan’s Mochida Pharmaceutical an exclusive license for the supply, co-development and co-marketing of daridorexant, Idorsia’s dual orexin receptor antagonist (DORA), for insomnia and related disorders in Japan. 5 December 2019
Pharmaceutical
German family-owned drugmaker Grünenthal and the University Hospital RWTH Aachen have entered into a research collaboration to develop new treatment approaches for patients with neuropathic pain. 5 December 2019
Biotechnology
Privately-held US biotech Tetra Therapeutics has presented data showing that TNF-blocking agents reduce the risk of Alzheimer’s disease in patients with rheumatoid arthritis or psoriasis. 5 December 2019
Biotechnology
US biotech firm Axsome Therapeutics yesterday announced that its AXS-12 (reboxetine) met the prespecified primary endpoint and significantly reduced the number of cataplexy attacks as compared to placebo in patients with narcolepsy in the CONCERT Phase II trial. 4 December 2019
Biotechnology
Australian plasma and cell and gene therapy specialist CSL Limited is steadily advancing its R&D pipeline and capabilities to deliver a highly differentiated product portfolio mix, addressing a broader range of patients’ unmet needs,” said head of Research & Development Dr William Mezzanotte today. 4 December 2019
Biotechnology
Privately-held UK biotech Mission Therapeutic and US major AbbVie today announced the identification of several deubiquitylating enzymes (DUBs) as potential drug targets in their Alzheimer’s and Parkinson’s R&D collaboration. 3 December 2019
Pharmaceutical
UK drugmaker AstraZeneca has agreed to sell the US and Canadian rights to psychiatric meds Seroquel (quetiapine fumarate) and Seroquel XR (quetiapine fumarate) to Germany’s Cheplapharm. 3 December 2019
Biotechnology
US biotech Neurocrine Biosciences and Canada’s Xenon Pharmaceuticals today announced a license and collaboration agreement to develop first-in-class treatments for epilepsy. 2 December 2019
Pharmaceutical
Ireland-incorporated Allergan’s ubrogepant is currently in pre-registration for the treatment of acute migraines. 2 December 2019
Generics
Drugmakers Pfizer and Flynn Pharma might not yet be off the hook over hefty fines handed out by the UK’s competition authority that the companies claim were unlawful. 29 November 2019
Biotechnology
Singapore-based TauRx has announced the publication of unexpected results of its drug hydromethylthionine, or LMTM, in patients with mild-to-moderate Alzheimer's disease. 27 November 2019
Pharmaceutical
Swedish drug developer Orexo today announced it has acquired the exclusive US rights to vorvida, a digital therapy for the treatment of alcohol use disorder (AUD), from GAIA AG, a global leader in digital therapeutics. 27 November 2019
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Pharmaceutical
Sage Therapeutics will down tools on its dalzanemdor program, after the Phase II DIMENSION trial missed both primary and secondary endpoints. 21 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Last week saw US pharma major AbbVie release disappointing Phase II trial results on its emraclidine in schizophrenia, which benefited Bristol Myers Squibb. Also on the research front, Germany’s Merck KGaA and Abbisko’s pimicotinib showed positive results in tenosynovial giant cell tumor (TGCT). M&A news saw German BioNTech punting $800 million upfront to acquire China based oncology focused Biotheus. Also of note, US drugmaker Halozyme Therapeutics made an unsolicited takeover bid for Evotec, valuing the German firm, at around 2 billion euros. 17 November 2024
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee (CHMP) made a number of recommendations at its November meeting, notable among which was a reversal of a previous rejection of Alzheimer’s drug Leqembi (lecanemab). 15 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Biotechnology
Swiss clinical-stage biopharma AC Immune saw its shares gain 8% to $3.38 in US trading this morning, after it released positive interim safety and immunogenicity data from the Phase II VacSYn clinical trial evaluating ACI-7104.056. 14 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of PTC Therapeutics’ gene therapy for the treatment of AADC (aromatic L-amino acid decarboxylase) deficiency, making it the first-ever gene therapy approved in the USA that is directly administered to the brain. 14 November 2024
Pharmaceutical
Digital therapeutics company GAIA has announced the signing of a licensing agreement for attexis with fellow German firm MEDICE Arzneimittel Pütter. 14 November 2024
Biotechnology
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover and develop novel treatments for Parkinson's disease, and another undisclosed neurodegenerative indication. 13 November 2024
Biotechnology
Neurogene has announced positive interim clinical data in the first four participants in the low-dose cohort of its ongoing Phase I/II open-label trial designed to evaluate NGN-401 gene therapy for the treatment of female pediatric patients with Rett syndrome. 13 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Pharmaceutical
US drugmaker AbbVie was trading more than 11% lower early on Monday afternoon in New York. 11 November 2024
Pharmaceutical
The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective and disease-modifying therapies (DMTs), says data and analytics company GlobalData in an overview of ongoing PD research.. 11 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze